GENSCRIPT BIO discloses Legend Biotech’s first-in-human LB2102 CAR-T results and new CARVYKTI® data presented at ASCO 2026

Bulletin Express

06/01

Genscript Biotech Corporation (GENSCRIPT BIO) issued a voluntary announcement on 1 June 2026 detailing R&D progress reported by its associate, Legend Biotech Corporation.

Legend Biotech filed a Form 6-K with the U.S. Securities and Exchange Commission and released a concurrent press statement highlighting:

1. First-in-human clinical data for LB2102, a DLL3-targeted CAR-T cell therapy, in patients with relapsed or refractory small cell lung cancer (SCLC) or large-cell neuroendocrine carcinoma (LCNEC). 2. New analyses from the CARTITUDE program featuring CARVYKTI®, its B-cell maturation antigen-directed CAR-T therapy for multiple myeloma.

Both data sets were presented at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting.

Management advised shareholders and potential investors to remain aware of market risks and exercise caution when trading the company’s securities.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1157001185"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1157001185\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1157001185?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-01 23:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1157001185","market":"us","top_or_hot":-1,"title":"GENSCRIPT BIO discloses Legend Biotech’s first-in-human LB2102 CAR-T results and new CARVYKTI® data presented at ASCO 2026","media":"Bulletin Express","content":"<p>Genscript Biotech Corporation (GENSCRIPT BIO) issued a voluntary announcement on 1 June 2026 detailing R&D progress reported by its associate, Legend Biotech Corporation.</p>\n<p>Legend Biotech filed a Form 6-K with the U.S. Securities and Exchange Commission and released a concurrent press statement highlighting:</p>\n<p>1. First-in-human clinical data for LB2102, a DLL3-targeted CAR-T cell therapy, in patients with relapsed or refractory small cell lung cancer (SCLC) or large-cell neuroendocrine carcinoma (LCNEC).  \n2. New analyses from the CARTITUDE program featuring CARVYKTI®, its B-cell maturation antigen-directed CAR-T therapy for multiple myeloma.</p>\n<p>Both data sets were presented at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting.</p>\n<p>Management advised shareholders and potential investors to remain aware of market risks and exercise caution when trading the company’s securities.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GENSCRIPT BIO discloses Legend Biotech’s first-in-human LB2102 CAR-T results and new CARVYKTI® data presented at ASCO 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGENSCRIPT BIO discloses Legend Biotech’s first-in-human LB2102 CAR-T results and new CARVYKTI® data presented at ASCO 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-01 23:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Genscript Biotech Corporation (GENSCRIPT BIO) issued a voluntary announcement on 1 June 2026 detailing R&D progress reported by its associate, Legend Biotech Corporation.</p>\n<p>Legend Biotech filed a Form 6-K with the U.S. Securities and Exchange Commission and released a concurrent press statement highlighting:</p>\n<p>1. First-in-human clinical data for LB2102, a DLL3-targeted CAR-T cell therapy, in patients with relapsed or refractory small cell lung cancer (SCLC) or large-cell neuroendocrine carcinoma (LCNEC).  \n2. New analyses from the CARTITUDE program featuring CARVYKTI®, its B-cell maturation antigen-directed CAR-T therapy for multiple myeloma.</p>\n<p>Both data sets were presented at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting.</p>\n<p>Management advised shareholders and potential investors to remain aware of market risks and exercise caution when trading the company’s securities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01548","symbol_name":"金斯瑞生物科技","start_time":0,"source_url":"","article_id":"1157001185","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1157001185","pubTimestamp":1780326204,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Genscript Biotech Corporation (GENSCRIPT BIO) issued a voluntary announcement on 1 June 2026 detailing R&D progress reported by its associate, Legend Biotech Corporation. Legend Biotech filed a Form...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01548":"金斯瑞生物科技"},"translate_title":"金斯瑞生物披露传奇生物首次人体LB2102 CAR-T结果及新CARVYKTI®ASCO 2026上公布的数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1},"content_text":"Genscript Biotech Corporation (GENSCRIPT BIO) issued a voluntary announcement on 1 June 2026 detailing R&D progress reported by its associate, Legend Biotech Corporation.\nLegend Biotech filed a Form 6-K with the U.S. Securities and Exchange Commission and released a concurrent press statement highlighting:\n1. First-in-human clinical data for LB2102, a DLL3-targeted CAR-T cell therapy, in patients with relapsed or refractory small cell lung cancer (SCLC) or large-cell neuroendocrine carcinoma (LCNEC).  \n2. New analyses from the CARTITUDE program featuring CARVYKTI®, its B-cell maturation antigen-directed CAR-T therapy for multiple myeloma.\nBoth data sets were presented at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting.\nManagement advised shareholders and potential investors to remain aware of market risks and exercise caution when trading the company’s securities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}